Photo from wikipedia
The newer direct‐acting oral anticoagulants (DOACs) – apixaban, dabigatran, edoxaban, rivaroxaban – offer many advantages over older anticoagulants such as warfarin. However, in order to optimise their benefits, it is… Click to show full abstract
The newer direct‐acting oral anticoagulants (DOACs) – apixaban, dabigatran, edoxaban, rivaroxaban – offer many advantages over older anticoagulants such as warfarin. However, in order to optimise their benefits, it is important that patients taking them do not become too blasé, advises Angus Thompson.
Keywords:
acting oral;
oral anticoagulants;
direct acting;
opportunities optimise;
optimise direct
Journal Title: Prescriber
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Prescriber
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!